<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04165122</url>
  </required_header>
  <id_info>
    <org_study_id>HTX101-02G</org_study_id>
    <nct_id>NCT04165122</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection</brief_title>
  <acronym>MATCH-2</acronym>
  <official_title>A Randomized, Double-Blind, Double-Dummy Phase II Study of Single Dose HDIT101 Versus Standard of Care Valaciclovir in Patients With Chronic Recurrent Anogenital HSV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg ImmunoTherapeutics GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg ImmunoTherapeutics GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, double-dummy study of single dose HDIT101 versus Standard&#xD;
      of Care Valaciclovir.&#xD;
&#xD;
      HSV-2-positive patients with at least 4 anogenital herpes lesions in the last 12 months (or&#xD;
      at least 2 herpes lesions with previous valaciclovir long-term therapy) can be included.&#xD;
&#xD;
      If a patients develops a anogenital Herpes lesion within 4 months after the screening visit,&#xD;
      the patients will be randomized in a 2:1 ratio to HDIT i.v. infusion + episodic treatment&#xD;
      with 500 mg Valaciclovir-placebo OR to a single HDIT placebo infusion + episodic treatment&#xD;
      with 500 mg Valaciclovir orally bid for 3 days.&#xD;
&#xD;
      Study duration per patient will be 180 days starting with the randomization visit. In&#xD;
      addition to the randomization visit, 4 visits at the site and 2 phone calls are scheduled.&#xD;
&#xD;
      At every occurence of a herpetic lesion during the study, patients are treated with&#xD;
      Valaciclovir/ Valaciclovir-placebo and need to present at the site twice to document start&#xD;
      and end date of the lesion (unscheduled visits).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this trial, patients with chronic recurrent herpes simplex virus (HSV-2) infections (with&#xD;
      at least 4 herpes lesions in the last 12 months or at least 2 herpes lesions with previous&#xD;
      valaciclovir long-term therapy) can be included.&#xD;
&#xD;
      After signature of ICF and during the screening period, the patients take daily swabs of the&#xD;
      anogenital area for 28 days to determine HSV shedding.&#xD;
&#xD;
      Patients not developing a lesion within 4 months after screening are not randomised. Patients&#xD;
      developing a lesion within 4 months can be randomised and the treatment must be initiated&#xD;
      within 72 Hours upon lesion occurence.&#xD;
&#xD;
      Approximately 125 patients will be randomized in a 2:1 ratio to one of the following&#xD;
      treatment groups:&#xD;
&#xD;
        -  Arm A: single HDIT i.v. infusion applied over 1 hour at the randomization visit +&#xD;
           episodic treatment with 500 mg Valaciclovir-placebo orally bid for 3 days.&#xD;
&#xD;
        -  Arm B: single HDIT placebo i.v. infusion applied over 1 hour at the randomization visit&#xD;
           + episodic treatment with 500 mg Valaciclovir orally bid for 3 days.&#xD;
&#xD;
      The HDIT101/HDIT101-placebo infusion is only applied once during the trial, Valaciclovir (or&#xD;
      corresponding placebo) has to be taken upon every occurence of another Herpes lesion.&#xD;
&#xD;
      Study duration per Patient will be 180 days starting with the randomization visit. In&#xD;
      addition to the randomization visit, 4 visits at the site and 2 phone calls are scheduled.&#xD;
&#xD;
      In case of developing another lesion after the randomization visit, patients take a single&#xD;
      swab of the lesion and episodic SoC treatment with Valaciclovir/ Valaciclovir-placebo is&#xD;
      started and documented in an electronic diary by the patient within 24 hours after&#xD;
      development of first symptoms. Quality of life is also recorded.&#xD;
&#xD;
      In addition to this, the patients need to present at the site within 72 hours after occurence&#xD;
      of a the new herpes outbreak for medical examination and to confirm the HSV-2 lesion. At this&#xD;
      unscheduled visit at the site, the PI will take a second swab and assess the lesion&#xD;
      (including start date). Another unscheduled visit will take place upon healing of lesion.&#xD;
&#xD;
      This procedure will be repeated for every outbreak during the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Double-Dummy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Block randomisation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of days with lesion(s) per treatment group</measure>
    <time_frame>180 days</time_frame>
    <description>Primary objective is calculated as the number of days with lesion (except the lesion episode at randomization) divided by the number of study days after IMP infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first recurrence of lesion</measure>
    <time_frame>180 days</time_frame>
    <description>Time to first recurrence of lesion as reported by patient and verified by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of lesions</measure>
    <time_frame>180 days</time_frame>
    <description>Recurrence rate is defined as number of recurrences divided by the total number of study days after IMP infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of recurrent lesions</measure>
    <time_frame>180 days</time_frame>
    <description>Duration of recurrent lesions is calculated as consecutive days with lesions of HSV score 2-7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific symptoms</measure>
    <time_frame>180 days</time_frame>
    <description>Disease-specific symptoms assessed by Herpes Symptoms Checklist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Herpes outbreak impact</measure>
    <time_frame>180 days</time_frame>
    <description>Herpes outbreak impact assessed by Herpes Outbreak Impact Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>180 days</time_frame>
    <description>Change in QoL between baseline and EoS assessed by the Recurrent Genital Herpes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Herpes Genitalis</condition>
  <arm_group>
    <arm_group_label>HDIT101 + Valaciclovir placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A:&#xD;
Patients treated with a single i.v. infusion of 2 g HDIT101 for 60 min at the randomization visit and with an episodic Valaciclovir placebo bid for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDIT101 placebo + Valaciclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B:&#xD;
Patients treated with a single i.v. infusion of HDIT101 placebo for 60 min at the randomization visit and with episodic Valaciclovir 500 mg twice daily for 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HDIT101</intervention_name>
    <description>i.v. Infusion</description>
    <arm_group_label>HDIT101 + Valaciclovir placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valaciclovir</intervention_name>
    <description>oral application of encapsulated Valaciclovir tablets</description>
    <arm_group_label>HDIT101 placebo + Valaciclovir</arm_group_label>
    <other_name>Valtrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HDIT101 placebo</intervention_name>
    <description>i.v. Infusion</description>
    <arm_group_label>HDIT101 placebo + Valaciclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valaciclovir placebo</intervention_name>
    <description>oral application of encapsulated Valaciclovir placebo tablets</description>
    <arm_group_label>HDIT101 + Valaciclovir placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years at the time of signing informed consent.&#xD;
&#xD;
          2. Signed informed consent for participation in the study.&#xD;
&#xD;
          3. Understanding, ability, and willingness to fully comply with study interventions and&#xD;
             restrictions.&#xD;
&#xD;
          4. Seropositive for HSV-2.&#xD;
&#xD;
          5. History of chronic recurrent anogenital HSV-2 infection with â‰¥ 4 outbreaks (â‰¥ 2 under&#xD;
             standard suppressive antiviral therapy) in the last year with no active lesion at time&#xD;
             of enrolment. Patients with acute lesion(s) can be enrolled when the previous lesion&#xD;
             is healed off.&#xD;
&#xD;
          6. No use of any HSV-suppressant therapy (both approved drugs and non-approved drugs&#xD;
             including OTC drugs) including topical applications at least 7 days prior to&#xD;
             enrolment.&#xD;
&#xD;
          7. Willingness to not use any topical or systemic anti-HSV therapy (both approved drugs&#xD;
             and non-approved drugs including OTC) during the study apart from the study&#xD;
             medication.&#xD;
&#xD;
          8. Willingness to not use any topical HSV treatment upon lesion development as well as&#xD;
             avoid any manipulation or physical impact, e.g., cooling of the lesion particularly in&#xD;
             the prodromal stage.&#xD;
&#xD;
          9. Medical assessment with no clinically significant morbidities or abnormalities as per&#xD;
             judgement of the investigator.&#xD;
&#xD;
         10. Women of child-bearing potential (WCBP) must have a negative beta-human chorionic&#xD;
             gonadotropin (Î²-HCG) urine and/or blood test at screening and within 72 hours before&#xD;
             receiving study treatment.&#xD;
&#xD;
         11. Willingness to use two independent effective contraceptive methods for 3 months after&#xD;
             Visit 1. Male participants and partners of female participants have to use a condom&#xD;
             during sexual intercourse or intimacy to reduce the probability of sexually&#xD;
             transmitted infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who do not develop a lesion during the 28-day swabbing period and 3 months&#xD;
             (90 days) afterwards (i.e., within 4 months after screening).&#xD;
&#xD;
          2. Medical history or current physical illnesses/medical conditions that constitute an&#xD;
             unacceptable risk for study participation in the judgment of the investigator (e.g.,&#xD;
             clinically significant autoimmune disorder, active infection, uncontrolled medical&#xD;
             conditions or organ system dysfunction that, in the investigator's opinion, could&#xD;
             compromise the patient's safety or put the study outcomes at risk, such as&#xD;
             uncontrolled hypertension, uncontrolled diabetes mellitus, uncontrolled coronary heart&#xD;
             disease, uncontrolled psychiatric condition).&#xD;
&#xD;
          3. Patients with herpes keratitis.&#xD;
&#xD;
          4. Immunomodulatory therapy including topical (e.g., rectal, vaginal, cutaneous, etc.)&#xD;
             and/or oral and/or parenteral and/or inhaling steroids within 28 days before start of&#xD;
             study treatment.&#xD;
&#xD;
          5. Any condition that precludes the sampling of up to 200 mL (additional 150 mL in case&#xD;
             of optional participation for exploratory objective (T-cell response)) blood over the&#xD;
             duration of the study.&#xD;
&#xD;
          6. Known resistance to or intolerance of valaciclovir or active substance or excipients&#xD;
             of the study medication.&#xD;
&#xD;
          7. Positive HIV antibody screen, hepatitis B virus (HBV) infection screen, or hepatitis C&#xD;
             virus (HCV) antibody screen.&#xD;
&#xD;
          8. Any known history of severe allergic or anaphylactic reactions.&#xD;
&#xD;
          9. Participation in any clinical study within the last 30 days prior to enrolment.&#xD;
&#xD;
         10. Prior participation in this or other clinical study with HDIT101.&#xD;
&#xD;
         11. Pregnant or breast-feeding women.&#xD;
&#xD;
         12. Prior malignant disease except basal cell carcinoma or carcinoma in situ which has&#xD;
             been successfully cured more than 5 years before enrolment.&#xD;
&#xD;
         13. Hemoglobin (Hb) &lt; 10 g/dL.&#xD;
&#xD;
         14. Creatinine (Crea) clearance (Cl) &lt; 40 mL/min (Cockcroft-Gault equation will be used)&#xD;
&#xD;
         15. Bilirubin &gt; upper limit of normal (ULN) x 2, except patients with known Morbus&#xD;
             Meulengracht.&#xD;
&#xD;
         16. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &gt; ULN x 3.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Kunz, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Heidelberg ImmunoTherapeutics GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Jessen2+Kollegen</name>
      <address>
        <city>Berlin</city>
        <zip>10777</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WIR &quot;Walk In Ruhr&quot; im St. Elisabeth Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infektio Research GmbH &amp; Co. KG</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Freiburg, Medizin II, Infektiologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICH Grindel</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Scholten und SchneeweiÃŸ GbR</name>
      <address>
        <city>Koeln</city>
        <zip>50674</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prinzmed</name>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herpes Genitalis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

